GEN Exclusives

More »

GEN News Highlights

More »
Oct 29, 2012

Rockland to Offer LIMR’s Preclinical Assays

  • Rockland Immunochemicals and Lankenau Institute for Medical Research (LIMR) expanded an existing licensing and commercialization agreement, to allow Rockland to market additional LIMR assays including the CellCountEZ® OxPhos™, RadDose™, and TiolEZ™ assays. The deal was arranged through LIMR’s business development subsidiary LIMR Development.

    Rockland provides antibodies and antibody-based tools for basic research, assay development, and preclinical studies. Founded in 1927, LIMR is a nonprofit biomedical research center with expertise in fields including cancer, cardiovascular disease, and diabetes. The institute’s CellCountEZ assay has been developed to allow the measurement of metabolically active cells while simultaneously quantifying cell death to determine cell viability, cell toxicity, or cellular proliferation.

    The OxPhos assay determines the cellular glutathione recycling capacity in tissue culture, or whole blood, to provide insights into oxidative stress during the aging process, and antioxidant levels/toxicology following chemotherapy. The RadDose assay is used for to measure ionizing radiation dose rates, while the Intracellular ThiolEZ assay is capable of determining total intracellular thiols, including glutathione and cysteine, as a means of investigating the aging, oxidative stress, antioxidant, chemotherapy response, and toxicology processes.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?